Last reviewed 2026-04-22 · How we verify

Dupilumab/Dupixent

Dupilumab/Dupixent is a Monoclonal antibody; IL-4 receptor antagonist Biologic drug developed by McMaster University. It is currently in Phase 3 development for Moderate-to-severe atopic dermatitis, Moderate-to-severe asthma with type 2 inflammation, Eosinophilic esophagitis.

Dupilumab is a monoclonal antibody that blocks the IL-4 receptor alpha subunit, inhibiting signaling of IL-4 and IL-13 cytokines to reduce type 2 inflammation.

Dupilumab is a monoclonal antibody that blocks the IL-4 receptor alpha subunit, inhibiting signaling of IL-4 and IL-13 cytokines to reduce type 2 inflammation. Used for Moderate-to-severe atopic dermatitis, Moderate-to-severe asthma with type 2 inflammation, Eosinophilic esophagitis.

At a glance

Mechanism of action

Dupilumab binds to IL-4 receptor alpha, a shared component of IL-4 and IL-13 signaling pathways that drive type 2 inflammatory responses. By blocking this receptor, it suppresses the production of IgE antibodies, reduces eosinophil recruitment, and decreases inflammatory mediator release. This mechanism addresses the underlying pathophysiology of multiple type 2 inflammatory diseases including atopic dermatitis, asthma, and eosinophilic conditions.

Approved indications

• Moderate-to-severe atopic dermatitis
• Moderate-to-severe asthma with type 2 inflammation
• Eosinophilic esophagitis
• Chronic rhinosinusitis with nasal polyps

Common side effects

• Injection site reactions
• Conjunctivitis
• Headache
• Oropharyngeal pain
• Herpes simplex infection

Key clinical trials

• A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (PHASE3)
• An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic Dermatitis (PHASE1)
• A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (PHASE3)
• A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease. (PHASE4)
• Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC) (PHASE3)
• Viral and Epigenetic Influences in CRSwNP
• A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care
• Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Dupilumab/Dupixent CI brief — competitive landscape report
• Dupilumab/Dupixent updates RSS · CI watch RSS
• McMaster University portfolio CI

Frequently asked questions about Dupilumab/Dupixent

Related

• Drug class: All Monoclonal antibody; IL-4 receptor antagonist drugs
• Target: All drugs targeting IL-4 receptor alpha (IL-4Rα)
• Manufacturer: McMaster University — full pipeline
• Therapeutic area: All drugs in Immunology; Dermatology; Respiratory
• Indication: Drugs for Moderate-to-severe atopic dermatitis
• Indication: Drugs for Moderate-to-severe asthma with type 2 inflammation
• Indication: Drugs for Eosinophilic esophagitis